全文获取类型
收费全文 | 1621107篇 |
免费 | 134649篇 |
国内免费 | 2627篇 |
专业分类
耳鼻咽喉 | 21997篇 |
儿科学 | 53812篇 |
妇产科学 | 46953篇 |
基础医学 | 231352篇 |
口腔科学 | 47660篇 |
临床医学 | 142708篇 |
内科学 | 318900篇 |
皮肤病学 | 34521篇 |
神经病学 | 132205篇 |
特种医学 | 65544篇 |
外国民族医学 | 488篇 |
外科学 | 246911篇 |
综合类 | 39806篇 |
现状与发展 | 3篇 |
一般理论 | 546篇 |
预防医学 | 123991篇 |
眼科学 | 36906篇 |
药学 | 122400篇 |
3篇 | |
中国医学 | 2990篇 |
肿瘤学 | 88687篇 |
出版年
2018年 | 15112篇 |
2016年 | 13317篇 |
2015年 | 15426篇 |
2014年 | 21178篇 |
2013年 | 32055篇 |
2012年 | 43529篇 |
2011年 | 45834篇 |
2010年 | 26860篇 |
2009年 | 25893篇 |
2008年 | 43991篇 |
2007年 | 46277篇 |
2006年 | 47039篇 |
2005年 | 45677篇 |
2004年 | 44941篇 |
2003年 | 43021篇 |
2002年 | 42046篇 |
2001年 | 76335篇 |
2000年 | 78973篇 |
1999年 | 66948篇 |
1998年 | 18012篇 |
1997年 | 16553篇 |
1996年 | 16495篇 |
1995年 | 16177篇 |
1994年 | 15214篇 |
1993年 | 14349篇 |
1992年 | 55785篇 |
1991年 | 54153篇 |
1990年 | 52913篇 |
1989年 | 51115篇 |
1988年 | 47510篇 |
1987年 | 46845篇 |
1986年 | 44566篇 |
1985年 | 43134篇 |
1984年 | 32235篇 |
1983年 | 27734篇 |
1982年 | 16254篇 |
1981年 | 14553篇 |
1980年 | 13665篇 |
1979年 | 30660篇 |
1978年 | 21210篇 |
1977年 | 17888篇 |
1976年 | 16815篇 |
1975年 | 17702篇 |
1974年 | 21632篇 |
1973年 | 20799篇 |
1972年 | 18974篇 |
1971年 | 17872篇 |
1970年 | 16394篇 |
1969年 | 15357篇 |
1968年 | 14037篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications. 相似文献
2.
3.
4.
5.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
6.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
7.
8.
9.
10.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158